Figure 2. FIGURE 2: Three different engineered cell therapy strategies based on proteomic analysis.

A. A “Locking-on” CAR-T concept harnesses the high abundance and hematopoietic specificity of CD48 or CD38 binding to increase avidity of anti-BCMA CAR-T. B. Acute treatment with lenalidomide increases MUC-1 expression on myeloma cells, improving anti-MUC-1 CAR-T activity. C. Proof-of-concept of stand-alone CAR-T against CCR10 using its natural ligand CCL27 as an antigen recognition domain. Figure created with BioRender